AI-designed molecular glues could turn previously undruggable proteins into targets—and replace many injectable biologics with simple oral drugs.

Source thesis

Useful protein interactions are difficult to target systematically; some mechanisms rely on laborious discovery or complex treatment delivery. The report discusses Combine protein-interaction measurements with generative molecular design; Develop small molecules that induce, block or modulate interactions, including targeted protein degradation. Examples cited: Proxima, Auron Therapeutics, Plexium.